Welcome to our dedicated page for Kraig Biocraft Laboratories In news (Ticker: KBLB), a resource for investors and traders seeking the latest updates and insights on Kraig Biocraft Laboratories In stock.
Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) regularly issues detailed news releases about its work in recombinant spider silk and bioengineered fibers. The company describes itself as a world leader in spider silk technology and uses its news flow to report on production milestones, facility expansions, scientific progress, and commercial engagements.
News items often highlight advances in the company’s BAM-1 and BAM-1 Alpha hybrid silkworm lines, including selective breeding achievements that increase cocoon shell weight, throughput, and production efficiency. Kraig Biocraft Laboratories also reports on the launch and completion of spider silk production cycles, the deployment of BAM-1 Alpha as its primary production hybrid, and the integration of diapause egg management into its rearing operations.
Another recurring theme in KBLB news is the build-out of production infrastructure in Southeast Asia. Releases cover topics such as taking possession of additional silkworm rearing centers, relocating facilities to protected highlands, and maintaining multiple, parallel production sites to support scalability and resilience. The company also reports on securing usage rights to government-owned mulberry gardens and taking control of mulberry fields dedicated to its operations, emphasizing feedstock security and vertical coordination.
Investors and observers can also find updates on commercial and research developments, including pilot programs with a globally recognized performance sports apparel brand and announcements about scientific leadership and breakthroughs in advanced fibers and bioengineered materials. Together, these news items provide an ongoing view into Kraig Biocraft Laboratories’ efforts to expand spider silk production capacity, refine its technology, and pursue high-value applications in performance textiles, technical apparel, and other markets.
Kraig Biocraft Laboratories (OTCQB: KBLB) has secured a $10 million standby equity purchase agreement (SEPA) with YA II PN, (Yorkville) to support its spider silk production expansion and commercialization efforts. The agreement provides flexible access to capital over the next 36 months, with no minimum use requirements or operational restrictions.
The SEPA is designed to help bridge the company's transition to revenue generation, allowing Kraig Labs to strategically access funds for building production capacity, developing spider silk inventory, creating new consumer products, and establishing sales partnerships. The company maintains full discretion over if and when to utilize this funding.
Kraig Biocraft Laboratories (OTCQB: KBLB) has announced a breakthrough in spider silk technology with the successful creation of a new transgenic inspired by the Darwin's bark spider. The company has integrated key genetic sequences from the Darwin's bark spider, known for producing the toughest biological material ever measured (10 times tougher than para-aramid fibers used in bulletproof vests), into their proprietary silkworms.
This development combines the exceptional properties of Darwin's bark spider silk with traditional silkworm silk production efficiency, targeting applications in textile, defense, medical, and industrial sectors. The company's COO, Jon Rice, indicated that this breakthrough is one of many recent achievements, with expectations for continued developments in 2025 alongside metric ton production of existing hybrids.
Kraig Biocraft Laboratories (OTCQB: KBLB) reports significant achievements in 2024 with its BAM-1 hybrids, the world's first commercially viable silkworms for recombinant spider silk production. The breakthrough technology has demonstrated remarkable results, including doubled cocoon size compared to traditional silkworms and enhanced silk yields. The company produced over 1,200 pounds of recombinant spider silk cocoons this year.
The BAM-1 hybrids' exceptional robustness and resilience have advanced scalability and consistency for large-scale commercial operations. Applications include technical textiles, defense, medical devices, and performance apparel. The company plans to expand production to multiple tons of spider silk in 2025.
Kraig Biocraft Laboratories (OTCQB: KBLB) has achieved a significant production milestone, manufacturing over 1,200 pounds of recombinant spider silk cocoon in the past 12 months. This output exceeds the combined production of all previous years, marking a major breakthrough in commercialization efforts.
The record-setting production was achieved through the company's newest hybrid spider silk production strain, which modified traditional silkworms to produce spider silk-based fibers. This advancement demonstrates Kraig Labs' success in scaling up from laboratory innovation to sustainable commercial production, positioning the company to address global demand for performance fibers across various consumer markets.
Kraig Biocraft Laboratories (OTCQB: KBLB) announced an investor web conference scheduled for December 4, 2024, at 4:30 pm ET. The conference will showcase the company's achievements in commercializing spider silk fibers over the past year. CEO Kim Thompson highlighted record-setting progress in scaling up spider silk production and developing next-generation super fibers. The presentation will be available on the company's website and YouTube channel, covering business model progress and upcoming targets.
Kraig Biocraft Laboratories (OTCQB: KBLB) has successfully completed its fourth production cycle for 2024, achieving record-setting performance in parental silkworm lines and hybrid cocoons. The latest batch set new records for cocoon size, shell weight, and other key metrics for large-scale production of their BAM-1 spider silk line. The company reports improvements in both hybrid cocoons and parental silkworm lines, demonstrating comprehensive advancements throughout the production process. These achievements strengthen their position in sustainable, high-performance fiber production and indicate readiness for scaling to multi-ton production levels.
Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB), the leading developer of spider silk-based fibers, has announced plans to host an investor web conference in the coming weeks. The conference will provide an in-depth review of the Company's progress over the past twelve months in commercializing its revolutionary spider silk technology.
The upcoming conference will cover recent advancements, detailed production metrics, and critical developments accelerating Kraig Labs' trajectory to bring its spider silk technology to market. Attendees can expect insights into total spider silk production, development of next-generation spider silk fibers, targeted markets for early adoption, and projections for production levels in 2024.
Company Founder and CEO, Kim Thompson, expressed excitement about sharing the substantial progress made in scaling up spider silk production. The Company is finalizing event details, with a follow-up announcement to be made as the event approaches.
Kraig Biocraft Laboratories (OTCQB: KBLB) announces the near completion of its largest production batch of BAM-1 parental line spider silk silkworms. This milestone marks the achievement of true commercial-scale levels of parental strain production. The current batch is cocooning this week, with the production team reporting strong growth and great colony health.
CEO Kim Thompson states this production cycle will deliver the largest supply of BAM-1 production hybrid eggs in the company's history. This success verifies the scalability of Kraig Labs' spider silk technology, positioning the company to deliver commercial quantities to partners and customers. The results will supply Kraig Labs with millions of BAM-1 production hybrids for commercial production, marking a transition from development to a true production focus.
Kraig Biocraft Laboratories (OTCQB: KBLB) has launched its largest production cycle of the BAM-1 spider silk line, more than doubling its previous single-batch caterpillar production record. The company is leveraging its new production rearing center to maximize capacity. The batch is divided into two groups:
1. 20% BAM-1 hybrids for reeling finished silk
2. 80% split evenly between two BAM-1 parental lines for crossbreeding
This strategy aims to quickly ramp up first-generation BAM-1 hybrid egg production. The record-setting cycle demonstrates Kraig Labs' commitment to scaling up production of advanced silk materials, positioning the company to meet diverse market needs and move closer to full-scale commercial production.
Kraig Biocraft Laboratories (OTCQB: KBLB) has launched its first production cycle for BAM-1 parental strains at a newly established production center. The facility is eight times larger than the previous one and has the capacity to support the production of 25 metric tons of spider silk per year when fully utilized. This expansion marks a significant milestone in the company's growth and its commitment to transforming the textile industry.
The new production center is strategically located to optimize operations and provide easy access to supporting infrastructure. It was built to address production space requirements for 2025 and create a foundation for future expansion. Kraig Labs anticipates building additional production capacity in 2025 to bring more silk production online for 2026.
FAQ
What is the current stock price of Kraig Biocraft Laboratories In (KBLB)?
What is the market cap of Kraig Biocraft Laboratories In (KBLB)?
